FDA approves first vaccine for respiratory syncytial virus
Drug Discovery World
JUNE 6, 2023
The US Food and Drug Administration (FDA) has approved Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo in individuals 60 years and older. A vaccine to help prevent RSV had been an elusive public health goal for more than half a century.
Let's personalize your content